142_CD
GlaxoSmithKline_NN
Financial_NN
record_NN
Quarterly_JJ
trend_NN
An_DT
unaudited_JJ
analysis_NN
is_VPRT [BYPA]
provided_VBN
by_PIN
quarter_NN
of_PIN
the_DT
Group_NN
results_NN
in_PIN
sterling_GER
for_PIN
the_DT
financial_JJ
year_NN
2002_CD
._.
The_DT
analysis_NN
comprises_VPRT
statutory_JJ
results_NN
,_,
business_NOMZ
performance_NN
results_NN
and_CC
pharmaceutical_JJ
sales_NN
by_PIN
therapeutic_JJ
area_NN
._.
Merger_NN
,_,
restructuring_GER
and_PHC
disposal_NN
of_PIN
subsidiaries_NN
Manufacturing_GER
and_CC
other_JJ
restructuring_GER
362 162 171 443_CD
90_CD
Merger_NN
costs_NN
and_PHC
product_NN
divestments_NOMZ
599_CD
1,069_CD
895_CD
Other_JJ
items_NN
50_CD
421_CD
22_CD
29_CD
721_CD
Loss_NN
profit_NN
before_IN
taxation_NOMZ
1,011_CD
1,652_CD
702 472 811_CD
Loss_NN
profit_NN
attributable_JJ
to_PIN
shareholders_NN
712_CD
1,330_CD
452 347 512_CD
Business_NOMZ
performance_NN
results_NN
-_:
retained_VBN
businesses_NOMZ
Sales_NN
21,212_CD
20,489_CD
18,079_CD
16,164_CD
14,938_CD
R&D_NN
expenditure_NN
2,732_CD
2,555_CD
2,510_CD
2,285_CD
2,072_CD
per_PIN
cent_NN
of_PIN
sales_NN
13_CD
12_CD
14_CD
14_CD
14_CD
Trading_GER
profit_NN
6,694_CD
6,053_CD
5,026_CD
4,378_CD
4,191_CD
per_PIN
cent_NN
of_PIN
sales_NN
32_CD
30_CD
28_CD
27_CD
28_CD
Net_JJ
interest_NN
payable_JJ
141 88 182 162_CD
192_CD
profit_NN
before_IN
taxation_NOMZ
6,517_CD
6,169_CD
5,327_CD
4,683_CD
4,299_CD
Adjusted_VBN
earnings_GER
profit_NN
attributable_JJ
to_PIN
shareholders_NN
4,627_CD
4,383_CD
3,654_CD
3,406_CD
2,892_CD
Business_NOMZ
performance_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
primary_JJ
performance_NN
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
,_,
is_VPRT [PASS]
presented_VBN
after_IN
excluding_VBG
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_CC
the_DT
disposal_NN
of_PIN
businesses_NOMZ
._.
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
exclusion_NN
of_PIN
these_DEMO
non-recurring_JJ
items_NN
provides_VPRT
a_DT
better_JJ
comparison_NN
of_PIN
business_NOMZ
performance_NN
for_PIN
the_DT
periods_NN
presented_VBN
._.
Accordingly_RB
,_,
this_DEMO
information_NOMZ
is_VPRT [PASS]
provided_VBN
as_IN
a_DT
supplement_NOMZ
to_PIN
that_DEMP
included_VBN
in_PIN
the_DT
Consolidated_NN
statement_NOMZ
of_PIN
profit_NN
and_PHC
loss_NN
on_PIN
pages_NN
76_CD
and_CC
77_CD
prepared_JJ
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
Statutory_JJ
results_NN
include_VPRT
these_DEMO
non-recurring_JJ
items_NN
._.
Share_NN
statistics_NN
Earnings_GER
per_PIN
Share_NN
p_NN
66.2_CD
50.3_CD
67.7_CD
50.3_CD
39.9_CD
Dividends_NN
per_PIN
GlaxoSmithKline_NN
share_NN
p_NN
:_:
GlaxoSmithKline_NN
shareholder_NN
40.0_CD
39.0_CD
Glaxo_NN
Wellcome_NN
shareholder_NN
38.0_CD
37.0_CD
36.0_CD
SmithKline_NN
Beecham_NN
shareholder_NN
29.66_CD
26.69_CD
24.02_CD
Dividends_NN
per_PIN
GlaxoSmithKline_NN
ADS_NN
$_$
:_:
GlaxoSmithKline_JJ
shareholder_NN
1.24_CD
1.11_CD
Glaxo_NN
Wellcome_NN
shareholder_NN
1.10_CD
1.14_CD
1.19_CD
SmithKline_NN
Beecham_NN
shareholder_NN
0.87_CD
0.86_CD
0.81_CD
Dividends_NN
are_VPRT [PASS]
expressed_VBN
in_PIN
terms_NN
of_PIN
a_DT
GlaxoSmithKline_NN
share_NN
ADS_NN
._.
On_PIN
the_DT
merger_NN
between_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
on_PIN
27th_JJ
December_NN
2000_CD
,_,
shareholders_NN
and_PHC
ADR_NN
holders_NN
received_VBD
shares_NN
in_PIN
GlaxoSmithKline_NN
in_PIN
the_DT
following_JJ
ratios_NN
:_:
for_PIN
1_CD
Glaxo_NN
Wellcome_NN
share_NN
1_CD
GlaxoSmithKline_NN
share_NN
for_PIN
1_CD
SmithKline_NN
Beecham_NN
share_NN
0.4552_CD
GlaxoSmithKline_NN
shares_NN
for_PIN
1_CD
Glaxo_NN
Wellcome_NN
ADS_NN
1_CD
GlaxoSmithKline_NN
ADS_NN
for_PIN
1_CD
SmithKline_NN
Beecham_NN
ADS_NN
1.138_CD
GlaxoSmithKline_NN
ADSs_NN
1_CD
GlaxoSmithKline_NN
ADS_NN
represents_VPRT
2_CD
GlaxoSmithKline_NN
shares_NN
._.
It_PIT
excludes_VPRT
those_DEMO
employees_NN
who_WP [WHSUB]
are_VPRT [PASS]
employed_VBN
and_PHC
managed_VBN
by_PIN
GlaxoSmithKline_NN
on_PIN
a_DT
contract_NN
basis_NN
._.
